Duchenne muscular dystrophy
The biggest genetic killer of children worldwideDuchenne is 100% fatal. There is currently no cure. But with your support, new treatments are coming through the pipeline that are helping to delay the progression of this devastating condition.
Early diagnosis, improved care and treatment options have also helped contribute to increased life expectancy.
Lack of dystrophin is the result of an error in the dystrophin gene, which is found on the X chromosome. As boys only have a single X chromosome, this error causes them to have Duchenne muscular dystrophy. Girls can be carriers of the genetic error, and in 1% of cases they can be sufferers.
The genetic error can be inherited from a female carrier. However, in a third of cases it is caused by a completely spontaneous genetic mutation – and therefore can happen to anyone.
1 in 3,500
boys born with
Duchenne
20,000
children born with Duchenne
in the world each year
100% FATAL
and there is
currently no cure
20s-30s
Average life
expectancy
The progression of Duchenne
Diagnosis and early ambulatory stage
Symptoms of Duchenne muscular dystrophy typically appear in the first few years of life. Children may struggle to sit or stand up independently, and may start to walk at a later age. They often have trouble keeping up with their peers. They have progressive muscle weakness of the legs and pelvic muscles. Their calves begin to enlarge, causing them to waddle when walking and making it difficult to climb stairs. Diagnosis is usually made by looking at raised creatine kinase enzymes in the blood. A muscle biopsy can also be done to look for abnormal levels of dystrophin, to confirm a diagnosis.
Late ambulatory stage
As the muscles begin to waste, children struggle with stairs and fall more often. They are unable to keep up with their peers and can have associated learning difficulties. Steroids are usually given to improve strength and prolong the ability to walk. However, long-term steroid use has a range of debilitating side effects. They can cause cataracts, as well as Cushing syndrome – a complex hormonal condition whose symptoms can include facial puffiness, weight gain, high blood pressure, osteoporosis and diabetes.
Early non-ambulatory stage
As children approach their teens they lose the ability to walk indepedently (known as ‘non-ambulant’), and may increasingly rely on the use of a wheelchair. Steroids delay the onset of puberty and cause individuals to have a shorter stature. Long-term steroid use makes young people more vulnerable to fractures and infection as it reduces bone density and immunity.
As the disease progresses, it causes severe muscle deterioration, reduced bone density and reduced cardiac and lung function. Muscle weakness and skeletal deformities often contribute to breathing disorders and scoliosis – and consequently, spinal surgery is common. Cardiomyopathy (an enlarged heart) occurs in almost all cases.
Late ambulatory stage
By their late teens and twenties, young adults with Duchenne will need need support for daily tasks such as eating, dressing, showering and going to the bathroom. Although their upper body mobility is impaired, many young adults can continue to use their fingers. They may require a feeding tube, may become dependent on a ventilator or respirator, or may later need a tracheotomy – a surgical procedure where an artificial opening is made in the throat and a tube is inserted to help air flow to the lungs. However improved care and treatments and improved life expectancy, mean young people can continue to play an active role in society.
Life expectancy
With improved knowledge and understanding of Duchenne, earlier diagnosis, care standards, and treatments, life expectancy has also increased. Young people with Duchenne often play an active role in society into their twenties, thirties and even forties.
The most common causes of death are breathing complications and heart failure, as the muscles of these essential organs deteriorate without repair. While there is no cure, there is hope in the form of new approved treatments, as well as treatments currently in clinical trial.
Our mission
Our impact
Your help
And there is still work to do.